Stay updated on Pembrolizumab vs Standard Therapy in MSI-H/dMMR Stage IV CRC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab vs Standard Therapy in MSI-H/dMMR Stage IV CRC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab vs Standard Therapy in MSI-H/dMMR Stage IV CRC Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    Revision label updated from v3.4.2 to v3.4.3 in the page footer.
    Difference
    0.0%
    Check dated 2026-03-11T12:56:09.000Z thumbnail image
  2. Check
    13 days ago
    No Change Detected
  3. Check
    20 days ago
    No Change Detected
  4. Check
    34 days ago
    Change Detected
    Summary
    A new revision label v3.4.2 was added and the previous v3.4.1 funding notice text was removed.
    Difference
    0.4%
    Check dated 2026-02-11T02:29:32.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    A site-wide notice about funding lapse and operating status was added, and the footer now shows Revision: v3.4.1, replacing the previous Revision: v3.4.0.
    Difference
    0.4%
    Check dated 2026-02-03T23:36:32.000Z thumbnail image
  6. Check
    49 days ago
    Change Detected
    Summary
    The Record History page now includes a glossary option and color-coded additions and deletions with revision metadata. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.5%
    Check dated 2026-01-27T22:44:07.000Z thumbnail image
  7. Check
    63 days ago
    Change Detected
    Summary
    Revision history shows a new entry for v3.3.4 and removal of v3.3.3, updating the page's version history. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-01-13T17:38:06.000Z thumbnail image
  8. Check
    84 days ago
    Change Detected
    Summary
    Footer updates include adding Revision: v3.3.3 and removing Revision: v3.3.2 plus removing the HHS Vulnerability Disclosure text, which are minor metadata changes that do not affect study content or user interaction. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-12-23T07:36:21.000Z thumbnail image

Stay in the know with updates to Pembrolizumab vs Standard Therapy in MSI-H/dMMR Stage IV CRC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs Standard Therapy in MSI-H/dMMR Stage IV CRC Clinical Trial page.